GlassScriptPhysician profile
Bernard A Stupski
NPI 1750571238
$17,255.64
in general payments reported to CMS, 2019-2025
14 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,935 · 2020: $5,209 · 2021: $2,859 · 2022: $98.24 · 2023: $490 · 2024: $192 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.27 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,821.12 | 2019-2025 | Mavyret, Creon |
| Abbott Laboratories | $362.22 | 2023-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Dexcom, INC. | $202.56 | 2019-2024 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $131.07 | 2019-2023 | Dovato |
| Pfizer INC. | $126.45 | 2019-2023 | |
| Medtronic Minimed, INC. | $121.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $82.32 | 2021 | |
| Janssen Products, LP | $81.58 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $76.15 | 2019 | |
| Amgen INC. | $71.13 | 2019 | |
| Glaxosmithkline, LLC. | $63.58 | 2019-2021 | |
| Hologic Sales and Service, LLC | $17.31 | 2022 | |
| Gilead Sciences, INC. | $17.25 | 2025 | Biktarvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Stupski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.